Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders
Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression
Software System for Analysis of Extremely Large Experimental Dataset and Multidimensional Drug Discovery
The National Institute on Aging, Laboratory of Neurosciences-Receptor Pharmacology Unit is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biomedical informatics.
Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation
Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer’s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to β-cell dysfunction. A hallmark feature of T2DM is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques and cause apoptosis of -cells of islets.
Topoisomerase III (TOP3) Inhibitors and Antiviral Compounds based on Cyanine Dyes
Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA, and thus has been a target of interest for the development of cancer therapies and RNA viral infection therapies. In the context of cancer, TOP3B is not an essential gene, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable to the inactivation of TOP3B. While inhibitors for other topoisomerases are among the most potent and widely used anticancer agents, there are no known inhibitors of TOP3B.
Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases
Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009. A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them. Thus there is a dire need to develop new therapeutic strategies with fewer side-effects. Immunotherapy has taken a lead among the new therapeutic approaches. Enhancing the innate immune response of an individual has been a key approach for the treatment against different diseases such as cancer an
MONOCLONAL ANTIBODIES DIRECTED TO PHOSPHORYLATED PSD95 AND USES THEREOF
Filed on 2022-11-17
ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE
Filed on 2022-10-19